Background Chloroquine (CQ) over three days plus primaquine (PQ) for seven days is the
treatment of choice of infections by Plasmodium vivax in Bolivia, where 95% of the cases of …

Data on chloroquine (CQ)-resistant Plasmodium vivax in Latin America is limited, even with
the current research efforts to sustain an efficient malaria control program in all these …

Reports from several sites in South America suggest the presence of isolated cases of
chloroquine-resistant Plasmodium vivax malaria. To investigate the possibility of …

In Colombia, published studies for the treatment of uncomplicated Plasmodium vivax
malaria with chloroquine–primaquine (CQ-PQ) are scarce. The aim of the study was to …

Emerging Plasmodium vivax resistance to chloroquine (CQ) may undermine malaria
elimination efforts in South America. CQ-resistant P. vivax has been found in the major port …

Abstract Background In Mexico, combined chloroquine (CQ) and primaquine (PQ) treatment
has been used since the late 1950s to treat Plasmodium vivax infections. Although malaria …

Background Plasmodium vivax resistance to chloroquine (CQ) has been reported
worldwide, although the World Health Organization clinical drug efficacy studies protocol …

The widespread use of primaquine (PQ) and chloroquine (CQ), together, may be
responsible for the relatively few, isolated cases of chloroquine‐resistant P. vivax (CQRPV) …

Chloroquine (CQ)-resistant Plasmodium vivax was first documented in 1989 and threatens
much of eastern Indonesia, with> 50% of therapeutic failure rates. We screened 2236 …

Background Chloroquine (CQ) and primaquine (PQ) are still the drugs of choice to treat
Plasmodium vivax malaria in many endemic areas, Brazil included. There is in vivo …